Welcome to our dedicated page for Varex Imaging news (Ticker: VREX), a resource for investors and traders seeking the latest updates and insights on Varex Imaging stock.
Varex Imaging Corporation (VREX) delivers critical x-ray components for medical diagnostics and industrial inspection systems worldwide. This page provides investors and industry professionals with a comprehensive resource for tracking the company's latest press releases, financial announcements, and strategic developments.
Find timely updates on quarterly earnings, new product launches, and partnerships that shape Varex's leadership in imaging technology. Our curated collection includes regulatory filings, manufacturing innovations, and market expansion updates across both medical and industrial segments.
Bookmark this page to monitor how Varex's advancements in digital detectors, x-ray tubes, and quality engineering impact global healthcare and industrial inspection markets. Check regularly for objective reporting on developments affecting the medical imaging supply chain and non-destructive testing solutions.
Varex Imaging (Nasdaq: VREX) announced its unaudited financial results for the second quarter of fiscal year 2024, with revenues of $206 million. The GAAP gross margin was 32%, while the Non-GAAP gross margin stood at 33%. GAAP net earnings were $0.03 per diluted share, and Non-GAAP net earnings were $0.16 per diluted share. Cash flow from operations was $3 million. The company reported a 10% year-over-year decrease in revenue, primarily due to lower sales in China. The medical segment revenue was down 15%, while the industrial segment revenue was up 6%. Non-GAAP gross margin was 33%, with Non-GAAP EPS decreasing to $0.16 from $0.26 in the previous year. Cash, cash equivalents, marketable securities, and CDs totaled $190 million at the end of the quarter. The company provided guidance for the third quarter, expecting revenues between $200 million and $220 million and Non-GAAP net earnings per diluted share between $0.05 and $0.25.